(Reuters) – The U.S. Food and Drug Administration has approved Novo Nordisk’s drug for the prevention or reduction of bleeding episodes in patients with a type of blood-related disorder called hemophilia A, the agency said on Friday.
(Reporting by Leroy Leo in Bengaluru; Editing by Alan Barona)
